We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While the overall price of generics under Medicare Part D fell since 2010, hundreds of products experienced “extraordinary” price hikes of at least 100 percent, the U.S. Government Accountability Office said. Read More
The U.S. Department of Justice issued grand jury subpoenas to Taro Pharmaceuticals and two of the company’s senior officials over the pricing of its generics, the drugmaker revealed in an SEC filing. Read More
A federal judge rescinded his own verdict backing the FDA’s decision to not grant Ferring exclusivity for its bowel preparation drug Preponik, ruling that the agency must give the company five-years of retroactive exclusivity. Read More
A federal judge rendered Janssen’s composition patent for Remicade invalid, marking a loss for the company engaged in ongoing efforts to block biosimilar competition. Read More
The U.S. Judicial Panel on Multidistrict Litigation is consolidating price-fixing suits against generics maker Covis Pharmaceuticals for its heart drug Lanoxin. Read More
In response to criticism surrounding the price of its EpiPen, Mylan plans to sell a generic version of its allergy treatment for half the price. Read More
A federal judge ruled that Apotex’s biosimilars of Amgen’s Neulasta and Neupogen do not infringe on a patent that covers a protein refolding process. Read More
Sen. Chuck Grassley (R-Iowa) has deemed Mylan’s response to his inquiry on the cost of the company’s allergy drug EpiPen “incomplete,” asking for further detail on its price-setting analyses and the product features. Read More